Stock Analysis, Dividends, Split History

DEPO / DepoMed, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price7.30
Volume940,100.00
Market Cap ($M)466.59
Enterprise Value ($M)409.35
Book Value ($M)191.21
Book Value / Share2.99
Price / Book2.44
NCAV ($M)-593.89
NCAV / Share-9.29
Price / NCAV-0.79
Share Statistics
Common Shares Outstanding 63,505,783
Common Stock Shares Outstanding 63,400,348
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.60
Return on Assets (ROA)-0.08
Return on Equity (ROE)-0.41
Balance Sheet (mrq) ($M)
Assets912.20
Liabilities720.99
Quick Ratio0.53
Current Ratio0.55
Income Statement (mra) ($M)
Sales Revenue Goods Gross0.00
Non Cash Royalty Revenue From Sale Of Future Royalties0.00
Royalty Revenue844,000.00
Sales Revenue Goods Net379,880,000.00
Revenues380,724,000.00
License And Services Revenue0.00
Sales Revenue Net0.00
Operating Income-42.18
Net Income-102.50
Earnings Per Share Basic-1.63
Earnings Per Share Diluted-1.63
Earnings Per Share Basic And Diluted-1.63
Cash Flow Statement (mra) ($M)
Cash From Operations62.17
Cash from Investing57.89
Cash from Financing57.89
Identifiers and Descriptors
CUSIP249908104
Central Index Key (CIK)1005201
Related CUSIPS
249908904 249908954

Split History

Stock splits are used by DepoMed, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

REPH: Recro Pharma Analysis and Research Report

10h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

11h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

11h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

Related News Stories

Collegium: Soft Reaction To Softer Growth

2018-08-10 seekingalpha
Collegium sees a continued sequential increase in sales, yet the market seems disappointed by the pace of growth. (1-1)

Depomed's (DEPO) CEO Arthur Higgins on Q2 2018 Results - Earnings Call Transcript

2018-08-08 seekingalpha
Good morning, and welcome to the Depomed, Inc. Second Quarter 2018 Financial Results Call. My name is Louis, and I will be facilitating the audio portion of today’s interactive broadcast. [Operator Instructions] At this time, I would like to turn the show over to Mr. John Thomas, Senior Vice President for Investor Relations and Corporate Communications. Mr. Thomas, you may begin your conference. (5-2)

PDL Biopharma: Sum-Of-The-Parts Analysis Suggests Downside Protection, And Optionality On Private Equity Investments

2018-07-27 seekingalpha
PDLI looks cheap based on its net cash, fair value of royalty contract and loan portfolios. (2-1)

Your Daily Pharma Scoop: IPO Review - Aptinyx Surges, Kezar Progresses, Neon Slumps

2018-07-11 seekingalpha
Aptinyx (APTX) priced its IPO at $16.00. 6.4M common stock shares were offered. Additional 959,999 shares were on underwriters over-allotment. Gross proceeds initially expected was ~102.4M, but reached $117.8M by the time of closing. The shares opened at $17.40 on June 21. The IPO closed on June 25. (28-2)

The Jury's Still Out On Depomed

2018-05-21 seekingalpha
DEPO's Q1 revenue was up 42% Y/Y on the strength of its commercialization deal with COLL. (10-0)

Silicon Investor Message Boards

This table lists all message boards related to DEPO / DepoMed, Inc. on message board site Silicon Investor.

Home Depot (HD) Home Depot (HD) Home Depot (HD) DEPO ride the coattails of a successful activist investor. DEPO ride the coattails of a successful activist investor. DEPO ride the coattails of a successful activist investor.
Molycorp - The Owner of the biggest US rare earth deposit Molycorp - The Owner of the biggest US rare earth deposit Molycorp - The Owner of the biggest US rare earth deposit FDIC: Federal Deposit Insurance Corporation FDIC: Federal Deposit Insurance Corporation FDIC: Federal Deposit Insurance Corporation
Eurozinc (EZM), VMS deposits in Portugal Eurozinc (EZM), VMS deposits in Portugal Eurozinc (EZM), VMS deposits in Portugal Avante Technologies AVQ -Humidifier through Home Depot Avante Technologies AVQ -Humidifier through Home Depot Avante Technologies AVQ -Humidifier through Home Depot
PPDD - Prepaid Depot PPDD - Prepaid Depot PPDD - Prepaid Depot ADTC-ADVANCED DEPOSITION ADTC-ADVANCED DEPOSITION ADTC-ADVANCED DEPOSITION
FDPO ... e-financial depot.com [Money to be Made?] FDPO ... e-financial depot.com [Money to be Made?] FDPO ... e-financial depot.com [Money to be Made?] FPGP: CollisionDepot.com...hassle-free repair/claims FPGP: CollisionDepot.com...hassle-free repair/claims FPGP: CollisionDepot.com...hassle-free repair/claims
CUSIP: 249908104